A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen. METHODS: Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin treatment regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy. RESULTS: A total of 204 patients were included in the safety analysis (104 received the standard regimen, and 100 received the high-dose regimen), and 197 were included in the efficacy analysis (102 and 95 in the standard and high-dose treatment groups, respectively). Patient demographic characteristics, neutropenia status (6.7% and 8.0% had neutropenia, respectively), and Acute Physiology and Chronic Health Evaluation II scores (mean, 16.5 and 17, respectively) were similar between treatment groups. Significant drug-related adverse events occurred in 1.9% of patients receiving the standard regimen and 3.0% of patients receiving the high-dose regimen (difference, 1.1%; 95% confidence interval, -4.1% to 6.8%). The most-common drug-related adverse events in the standard and high-dose treatment groups were phlebitis (3.8% and 2.0%, respectively), increased alkaline phosphatase level (6.9% and 2.0%, respectively), and increased aspartate transaminase level (4.0% and 2.0%, respectively). Overall, 71.6% of patients who received the standard regimen and 77.9% of patients who received the high-dose regimen had favorable overall responses (difference, 6.3%; 95% confidence interval, -5.9% to 18.4%; not statistically significant). Mortality at 8 weeks after therapy was similar between groups. CONCLUSIONS: Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“A study comparing a triple daily dose of caspofungin (150-mg daily) versus standard 50-mg daily dosing found no advantage for the higher dose [24].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [24]
In the citing paper
“Taken together, these studies show that higher than standard doses of echinocandins, while generally well tolerated, do not improve patient outcomes in most clinical scenarios.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [24]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“Adult patients (age, 18 years) were eligible for inclusion if they had both clinical and microbiological evidence of invasive candidiasis at a sterile site, in accordance with the criteria for proven invasive candidiasis described by the Mycosis Study Group and the European Organization for the Research and Treatment…”
MethodComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · cited 6×
“Follow-up procedures were as described elsewhere [6].”
BackgroundMethodResultInfluentialSelf-citationPractice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · cited 3×
“This was a multicenter, randomized, double-blind study conducted from January 2006 through January 2008 at 38 sites in North and South America, Europe, and Asia to evaluate the safety, tolerability, and efficacy of caspofungin at a dosage of 50 mg/day (after a 70-mg loading dose on day 1 of treatment), compared with c…”
MethodInfluentialAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationCandidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · cited 1×
“that among control individuals, with an attributable mortality of ∼30% [3, 4].”
BackgroundMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationEpidemiology of Nosocomial Fungal Infections, with Emphasis on Candida Species
Jarvis, W. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1526 · Cited by 636 · cited 2×
“nosocomial pathogens overall [1].”
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Nosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“that among control individuals, with an attributable mortality of ∼30% [3, 4].”
Background
Cited by
Items 101–200 of 220
Földi, R., Kovács, R., Gesztelyi, R., Kardos, G., Berényi, R., Juhász, B., Szilágyi, J., Mózes, J., & Majoros, L. (2012) · Mycopathologia · doi:10.1007/s11046-012-9554-7 · Cited by 22
Bayegan, S., Majoros, L., Kardos, G., Kemény-Beke, A., Miszti, C., Kovacs, R., & Gesztelyi, R. (2010) · The Journal of Microbiology · doi:10.1007/s12275-010-9221-y · Cited by 21
“However, these differences were statistically not significant and were not considered to be associated with the phenomenon of paradoxical growth (Pappas et al., 2007; Betts et al., 2009).”
BackgroundResultInfluentialTóth, Z., Forgács, L., Kardos, T., Kovács, R., Locke, J. B., Kardos, G., Nagy, F., Borman, A. M., Adnan, A., & Majoros, L. (2020) · Journal of Fungi · doi:10.3390/jof6030136 · Cited by 22
Bailly, S., Gautier‐Veyret, E., Lê, M., Bouadma, L., Andremont, O., Neuville, M., Mourvillier, B., Sonneville, R., Magalhaes, É., Lebut, J., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01545-20 · Cited by 19
Marcos-Zambrano, L. J., Escribano, P., Sánchez‐Carrillo, C., Bouza, E., & Guinea, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-16 · Cited by 20
“Since the procedure requires the catheter lumen to be filled with a solution containing a high concentration of echinocandins (13), the paradoxical effect may have a negative impact (14, 15).”
BackgroundPfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 21
“glabrata [44–49].”
Molecular Mechanisms of Antifungal Resistance in Mucormycosis
Ganesan, P., Ganapathy, D. M., Sekaran, S., Murthykumar, K., Sundramoorthy, A. K., Sivaperumal, P., & Rajeshkumar, S. (2022) · BioMed Research International · doi:10.1155/2022/6722245 · Cited by 18
“Surprisingly, even at higher doses (150 mg/day), no adverse e ff ects were observed in patients with invasive candidiasis [29].”
Szilágyi, J., Földi, R., Bayegan, S., Kardos, G., & Majoros, L. (2012) · Journal of Chemotherapy · doi:10.1179/1120009x12z.0000000005 · Cited by 21
Prażyńska, M. B., Bogiel, T., & Gospodarek-Komkowska, E. (2017) · Folia Microbiologica · doi:10.1007/s12223-017-0555-2 · Cited by 20
Muilwijk, E. W., Maertens, J. A., van der Velden, W. J. F. M., ter Heine, R., Colbers, A. P. H., Burger, D. M., Andes, D. R., Theunissen, K., Blijlevens, N. M. A., & Brüggemann, R. J. M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky324 · Cited by 19
Zaragoza, R., Ferrer, R., Maseda, E., Llinares, P., & Rodríguez, A. H. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2014.06.001 · Cited by 17
Shields, R. K., Nguyen, M. H., Press, E. G., & Clancy, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00095-11 · Cited by 18
“In this regard, it is notable that PD targets for caspofungin are readily achievable in vivo despite less-frequent administration due to the tolerability of high doses (4) and the persistence of therapeutic concentrations in tissues (13).”
BackgroundKovács, R., Gesztelyi, R., Berényi, R., Domán, M., Kardos, G., Juhász, B., & Majoros, L. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.066381-0 · Cited by 20
Efficacy and safety of caspofungin in obese patients
Ryan, D., Lupinacci, R. J., & Kartsonis, N. A. (2011) · Medical Mycology · doi:10.3109/13693786.2011.571293 · Cited by 16
Self-citationBalázsi, D., Tóth, Z., Locke, J. B., Borman, A. M., Forgács, L., Balla, N., Kovács, F., Kovács, R., Amano, C., Baran, T. I., et al. (2024) · Journal of Fungi · doi:10.3390/jof10090617 · Cited by 17
“Higher echinocandin exposure may increase survival; however, studies have shown that elevated daily doses of caspofungin and micafungin do not significantly increase the cure rates while simultaneously increasing the risk of liver damage [32,33].”
BackgroundWe can do better: a fresh look at echinocandin dosing
Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky013 · Cited by 15
Zaragoza, R., Llinares, P., Maseda, E., Ferrer, R., & Rodríguez, A. H. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.006 · Cited by 14
Safdar, A., Rodriguez, G. H., Zuniga, J., Akhrass, F. A., & Pande, A. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190013515927 · Cited by 14
“7 Comorbid medical conditions Diabetes mellitus 14 (15) 2 (7) 12 (19) .”
InfluentialCota, J. M., & Burgess, D. S. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0015-9 · Cited by 14
Girmenia, C., Finolezzi, E., Federico, V., Santopietro, M., & Perrone, S. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.013 · Cited by 17
Baud, F. J., Jullien, V., Desnos‐Ollivier, M., Lamhaut, L., & Lortholary, O. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107007 · Cited by 13
Yang, Q., Zhang, T., Zhang, Y., Sun, D., Zheng, X., Du, Q., Wang, X., Cheng, X., Xing, J., & Dong, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.993330 · Cited by 14
“These studies demonstrating that caspofungin is generally safe at higher doses (Betts et al., 2009; Cornely et al., 2011).”
Backgroundvan der Elst, K. C. M., Brüggemann, R. J. M., Rodgers, M. G. G., & Alffenaar, J. C. (2012) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2011.00716.x · Cited by 15
Földi, R., Szilágyi, J., Kardos, G., Berényi, R., Kovács, R., & Majoros, L. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.05.011 · Cited by 14
“Many authors suggest that the currently recommended echinocandin daily doses may be insufficient to clear Candida from the infected body site (Betts et al., 2009; Pappas et al., 2007; Sirohi et al., 2006). Notably, Howard et al. (2011) found weak fungistatic effect of 1 and 5 mg/kg daily doses of caspofungin, anidulaf…”
BackgroundResultInfluentialDose escalation studies with caspofungin against Candida glabrata
Domán, M., Kovács, R., Perlin, D. S., Kardos, G., Gesztelyi, R., Juhász, B., Bozó, A., & Majoros, L. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000116 · Cited by 15
Husni, R., Chrabieh, R., Dib, R. W., Vázquez, J. A., Guimarães, T., Fernandez, A. R., Khoury, R., Asmar, L., Khazen, G., Samaha, N. L., et al. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.031 · Cited by 13
“Others - Not Catheter Related Sources 19 (56) 3(9) 6 (9) 8 (40) 36 (30)”
Spriet, I., Meyfroidt, G., Maleux, G. A., Verslype, C., & Willems, L. (2012) · Pharmacology · doi:10.1159/000342906 · Cited by 13
Shibata, Y., Hagihara, M., Kato, H., Kawasumi, N., Hirai, J., Nishiyama, N., Asai, N., Koizumi, Y., Yamagishi, Y., Matsuura, K., et al. (2017) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2017.02.008 · Cited by 12
Extrapolating Antifungal Animal Data to Humans—Is It Reliable?
Stevens, V. M., Mueller, S. W., Reynolds, P., MacLaren, R., & Kiser, T. H. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00370-x · Cited by 12
Candida endocarditis: current perspectives on diagnosis and therapy
Ben‐Ami, R., Matteo, B., Bouza, E., Alex, K., & Vena, A. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.05.035 · Cited by 12
Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States
Reinhold, I., Mori, G., Lanzafame, M., Limongelli, A., Vena, A., Götz, J., Bauernfeind, S., Hanses, F., Tometten, L., Mayer, M., et al. (2025) · Mycoses · doi:10.1111/myc.70114 · Cited by 11
Caspofungin: when and how? The microbiologist’s view
Mayr, A., Aigner, M., & Lass‐Flörl, C. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02039.x · Cited by 13
Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients
Stergiopoulou, T., & Walsh, T. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1000302 · Cited by 11
“High dosages of echinocandins have been investigated in the adult population for treatment of invasive candidiasis or aspergillosis [52,53].”
BackgroundMetzke, B., Neubauer, W. C., Hieke, S., Jung, M., Wäsch, R., & Engelhardt, M. M. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3278 · Cited by 11
Animal Models In Mycology: What Have We Learned Over The Past 30 Years
Kirkpatrick, W. R., Wiederhold, N. P., Najvar, L. K., & Patterson, T. F. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0126-6 · Cited by 11
“Based on the concentration dependent activity of the echinocandins and the clinical safety profile of the echinocandins [72], dosage escalation of these agents has been evaluated as a strategy to overcome microbiologic resistance.”
BackgroundXie, J., Yang, Q., Han, X., Dong, Y., Zhang, T., Li, Y., Ji, M., Liu, C., Cai, Y., & Wang, Y. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-22 · Cited by 10
New antifungal agents for the treatment of candidaemia
Muñóz, P., Guinea, J., Rojas, L., & Bouza, E. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.007 · Cited by 14
“Page 7 of 29 Ac ce pt ed M an us cr ip t Another study suggested that higher doses of caspofungin did not improve clinical efficacy [27].”
BackgroundTang, B. H. E., Bay, J. W., Yeong, F. M., & Samuel, M. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101362 · Cited by 13
When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock
Allou, N., Allyn, J., & Montravers, P. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0204-x · Cited by 10
Chen, Y., Dhillon, S., Adomakoh, N., & Roberts, J. A. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2539427 · Cited by 9
Szilágyi, J., Földi, R., Gesztelyi, R., Bayegan, S., Kardos, G., Juhász, B., & Majoros, L. (2012) · Chemotherapy · doi:10.1159/000337088 · Cited by 9
Use of antifungal drugs in hematology
Nucci, M. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120095 · Cited by 10
Self-citationActualización en terapia antifúngica: nuevos fármacos e indicaciones
Fortün, J. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70042-8 · Cited by 17
Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients
Colombo, A. L., Agnelli, C., & Kontoyiannis, D. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa446 · Cited by 10
Abdul-Aziz, M. H., Diehl, A., Liu, X., Cheng, V., Corley, A., Gilder, E., Levkovich, B., McGuinness, S., Ordoñez, J., Parke, R. L., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01435-24 · Cited by 8
Adnan, A., Borman, A. M., Tóth, Z., Forgács, L., Kovács, R., Balázsi, D., Balázs, B., Udvarhelyi, G., Kardos, G., & Majoros, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051365 · Cited by 9
“Although larger daily echinocandin doses were well tolerated in clinical situations, a significantly better cure rate was not detected [32,33].”
BackgroundZanette, R. A., & Kontoyiannis, D. P. (2013) · Virulence · doi:10.4161/viru.25523 · Cited by 9
Dib, R. W., Hachem, R. Y., Chaftari, A., & RAAD, I. I. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.028 · Cited by 8
Clinical Insights: Antimicrobial Therapy for Infectious Uveitis
Leong, E., Cifuentes‐González, C., W., J. H. Y., Samy, R. P., Khairallah, M., Rojas-Carabali, W. A., Putera, I., de‐la‐Torre, A., & Agrawal, R. V. (2024) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2024.2345848 · Cited by 7
Development and Quality Control of a Population Pharmacokinetic Model Library for Caspofungin
Xu, N., Shi, Y., Wang, Y., Mak, W. Y., Yang, W., Ng, K. W., Wu, Y., Tang, Z., He, Q., Yan, G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060819 · Cited by 7
“For caspofungin, the current target values are derived from preclinical studies and are in urgent need of confirmation through clinical research.”
BackgroundUpdated guidelines for managing fungal diseases in hematology patients
Hicheri, Y., Toma, A., Maury, S., Pautas, C., Mallek, H., & Cordonnier, C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.85 · Cited by 10
Clinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 8
Pressiat, C., Aït‐Ammar, N., Daniel, M., Lesne-Hulin, A., Botterel, F., & Levesque, É. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01187-21 · Cited by 8
Antifungal Therapy in Eye Infections: New Drugs, New Trends
Joseph, J., & Sharma, S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2782-3_9 · Cited by 8
Gastine, S., Hempel, G., Neely, M. N., Walsh, T. J., & Groll, A. H. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac182 · Cited by 7
Treatment of breakthrough fungal infections: Is there one best drug strategy?
Nailor, M. D., & Chandrasekar, P. H. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0032-8 · Cited by 6
“Two trials of candidiasis, one comparing micafungin at 100 and 150 mg/day and the other comparing caspofungin at 50 and 150 mg/day, showed no improved response with the higher dose [32, 33 ].”
ResultCaspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety
de Paula, D. C. C., Leite, E. A., Araújo, C. M., Branquinho, R. T., Guimarães, H. N., & Grabe‐Guimarães, A. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-020-09599-x · Cited by 6
Candida Infections in Solid Organ Transplantation
Barros, N., & Mansour, M. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_43 · Cited by 7
Antifungal Dosing in Obesity: A Review of the Literature
Amsden, J. R., & Slain, D. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0049-7 · Cited by 6
“Safety studies using much higher doses have been performed in nonobese subjects [ 52 ].”
BackgroundPrépost, E., Tóth, Z., Perlin, D. S., Gesztelyi, R., Kardos, G., Kovács, R., Nagy, F., Forgács, L., & Majoros, L. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s198764 · Cited by 8
“This is in line with the widely accepted opinion that paradoxical growth may be confined to in vitro situations.(10,11,14,32)”
BackgroundResultAntifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts
Michallet, M., Sobh, M., Deray, G., Gangneux, J., Pigneux, A., Larrey, D. G., Ribaud, P., Mira, J. P., Nivoix, Y., Yakoub‐Agha, I., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.010 · Cited by 5
Self-citationZaragoza, R., Llinares, P., Maseda, E., Ferrer, R., & Rodríguez, A. H. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.005 · Cited by 4
Pantothenate kinase is an effective target for antifungal therapy
Regan, J., DeJarnette, C. A., Reitler, P., Gihaz, S., Srivastava, A., Ge, W., Tucker, K. M., Peters, T. L., Meibohm, B., Mamoun, C. B., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.007 · Cited by 6
Self-citationInvasive Candidiasis in the Neutropenic Cancer Patient
Gamaletsou, M. N., Sipsas, N. V., & Kontoyiannis, D. P. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0044-4 · Cited by 6
Innovative Antimykotika zur Therapie invasiver Pilzinfektionen
Glöckner, A. (2011) · Der Internist · doi:10.1007/s00108-011-2873-9 · Cited by 5
Penetration of echinocandins into wound secretion of critically ill patients
Gasperetti, T., Welte, R., Oberacher, H., Marx, J., Lorenz, I. H., Schellongowski, P., Staudinger, T., Burgmann, K., Eller, P., Santner, T., et al. (2021) · Infection · doi:10.1007/s15010-021-01604-x · Cited by 4
“caspofungin 150 mg daily, could be considered under close monitoring for toxicity [26].”
BackgroundScaling Adult Doses of Antifungal and Antibacterial Agents to Children
Dawson, T. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05307-11 · Cited by 4
“(1) previously reported results from clinical trials for such “high-dose caspofungin” that indicated a safe and somewhat more effective response than with the normal dose.”
ResultGroll, A. H., Schrey, D., & Walsh, T. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_6 · Cited by 6
Reitler, P., DeJarnette, C. A., Kumar, R., Tucker, K. M., Peters, T. L., Twarog, N. R., Shelat, A. A., & Palmer, G. E. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00484-25 · Cited by 4
Self-citationAntifungal Dosing in Critically Ill Patients
Bergman, S., Tyagi, I., & Ronald, K. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0012-z · Cited by 3
Antifungal Dosing Strategies for Critically Ill Patients
Dietrich, T., Pfeifer, C. J., Aker, K. E., & Bergman, S. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0270-0 · Cited by 3
Shibata, Y., Miyahara, Y., Sadaka, Y., Yasue, M., Fujimura, M., Soda, M., Yamamoto, M., Kato, H., Suzuki, A., Tsukamoto, K., et al. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.04.011 · Cited by 3
Vaezi, A., Badali, H., Fakhim, H., Nasri, E., & Yaghoobi, M. H. (2018) · International Journal of Enteric Pathogens · doi:10.15171/ijep.2018.23 · Cited by 2
Indication des traitements antifongiques (hors hématologie). Que montrent les données ?
Huette, P., & Dupont, H. (2019) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2019.03.004 · Cited by 2
OBEZ HASTALARDA ANTİMİKROBİYAL İLAÇ DOZLARI
Bahap, M., Ekinci, P. B., Bayraktar‐Ekincioglu, A., & Demirkan, K. (2019) · STED / Sürekli Tıp Eğitimi Dergisi · doi:10.17942/sted.598625 · Cited by 3
Nouwar, R. E., Lapique, E. L., Eynden, F. V., Martiny, D., Remmelink, M., Roussoulieres, A. L. S., & Hites, M. (2025) · Microorganisms · doi:10.3390/microorganisms13030580 · Cited by 2
Zaragoza, R., Llinares, P., Maseda, E., Ferrer, R., & Rodríguez, A. H. (2013) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2013.05.016 · Cited by 3
Shiohira, H., Nakamatsu, M., Kise, Y., Higa, F., Tateyama, M., HOKAMA, N., Kuniyoshi, Y., Ueda, S., Nakamura, K., & Fujita, J. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00296 · Cited by 2
Schrey, D., Walsh, T. J., & Groll, A. H. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00027-1 · Cited by 4
Prażyńska, M. B., & Gospodarek-Komkowska, E. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0123-2 · Cited by 2
Lanternier, F., & Lortholary, O. (2010) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2010.05.002 · Cited by 3
Yuan, S.-D., Wen, K.-L., Cao, Y., Huang, W., & Zhang, A. (2024) · Infection · doi:10.1007/s15010-023-02162-0 · Cited by 2
“In particular, the high-dose caspofungin treatment regimen have demonstrated good tolerability without dose-limiting toxicity, and the maximum tolerated dose of caspo-fungin seemed to be over 200 mg/day [20, 21].”
BackgroundUpdate on invasive opportunistic mycoses: Clinical trials review, 2008–2009
Groll, A. H. (2009) · Current Infectious Disease Reports · doi:10.1007/s11908-009-0060-0 · Cited by 2
Erratum to: An Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2014) · Infection · doi:10.1007/s15010-013-0577-x · Cited by 2
Shabanzadeh, M., Rezaei‐Matehkolaei, A., & Mahmoudabadi, A. Z. (2025) · Iranian Journal of Microbiology · doi:10.18502/ijm.v17i4.19261 · Cited by 1
“50 90 The minimum inhibito-effective first-line therapy for invasive candidiasis ry concentration (MIC), MIC , MIC , and MIC geo-by researchers (7, 8).”
Unveiling the Silent Threat: An Exploration of Fungal Infections in Critical Care Environments
Ahmed, M., Batarseh, S. F., Zghoul, S. A., Algoussous, A. N., & Innabi, A. (2025) · JAP Academy Journal · doi:10.4103/japaj.japaj_7_24 · Cited by 1
Colombo, A. L., Magri, M. M. C., Carlesse, F. A. D. M. C., Falci, D. R., Garnica, M., Santos, D. W. D. C. L., Queiroz‐Telles, F., & Pasqualotto, A. C. (2026) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2026.105946 · Cited by 2
“214,216 The choice of antifungal agents should, whenever feasible, be guided by the results of in vitro susceptibility testing.”
Self-citationCaspofungin exposure‐response relationships in adult patients with mucosal or invasive candidiasis
Comisar, W. A., Sun, P. G., Li, S., Sable, C. A., Schwartz, M. S., Bi, S., Chow, J. W., Ngai, A. L., Winchell, G. A., Kartsonis, N. A., et al. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.44 · Cited by 1
Self-citationStrategien bei Versagen einer antimykotischen Therapie auf Intensivstation
Arens, C., Bernhard, M., Koch, C., Heininger, A., Störzinger, D., Hoppe‐Tichy, T., Hecker, M., Grabein, B., Weigand, M. A., & Lichtenstern, C. (2015) · Der Anaesthesist · doi:10.1007/s00101-015-0072-0 · Cited by 1
Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans
Mueller, S. W., & Kiser, T. H. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0051-0 · Cited by 1
“Studies evaluating higher-dose echinocandin regimens have not demonstrated reduced efficacy or increased mortality with escalating dosage [40, 41].”
BackgroundKeiler, S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-16 · Cited by 1
Echinocandins for Prevention and Treatment of Invasive Fungal Infections
Johnson, M. D., & Mohr, J. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-14 · Cited by 2
A Brief Insight into Peptide and Non-Peptide Drugs of Fungal Origin
Mishra, A., Usha, P., & Sabareesh, V. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_22 · Cited by 1
Candida Infections in Hematopoietic and Solid Organ Transplant Recipients
Freifeld, A. G., & Kauffman, C. A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_32 · Cited by 1
Antifungal Therapy in Patients with Hematological Malignancies
Herbrecht, R., & Nivoix, Y. (2010) · Springer eBooks · doi:10.1007/978-3-642-15742-4_44 · Cited by 1
“Caspofungin is a well-tolerated antifungal drug [12, 83, 86, 127].”
Self-citationDeJarnette, C. A. (2020) · doi:10.21007/etd.cghs.2020.0518 · Cited by 2
De la bonne utilisation des antifongiques systémiques en réanimation
Timsit, J., Potton, L., Lugosi, M., Minet, C., Hamidfar-Roy, R., Ara-Somohano, C., Bonadona, A., & Schwebel, C. (2013) · Références en réanimation · doi:10.1007/978-2-8178-0389-0_7
Using Antifungal Pharmacodynamics to Improve Patient Outcomes
Wiederhold, N. P. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0010-1
“has also been evaluated in a recent study of patients with invasive candidiasis [ 55 ].”
ResultEchinocandins for candidemia: a rational choice
Menichetti, F., & Tagliaferri, E. (2013) · Reviews in Health Care · doi:10.7175/rhc.v4i2s.872
Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents
Heinz, W., & Klinker, H. (2012) · Journal of Laboratory Medicine · doi:10.1515/labmed-2011-0012 · Cited by 2
Metadata
- Authors
- Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., Strohmaier, K. M., Tucker, K. A., Taylor, A. F., Kartsonis, N. A., & Caspofungin High‐Dose Study Group
- Affiliations
- University of Rochester (US)
- Lehigh Valley Hospital (US)
- VA North Texas Health Care System (US)
- Hôpitaux Universitaires de Strasbourg (FR)
- University of Minnesota (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Kartsonis, Nicholas A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-06-15
- Volume
- 48
- Issue
- 12
- Pages
- 1676-1684
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168334830
- Cited by
- 214
- References
- 17
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 13 · 2019: 10 · 2018: 11 · 2017: 11 · 2016: 11 · 2015: 12 · 2014: 6 · 2013: 17 · 2012: 19
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, invasive candidiasis, antifungal therapy, drug safety, drug-related adverse events, microbiological clearance, treatment efficacy, phlebitis, liver enzymes, mortality, neutropenia, adult patients, echinocandins, fluconazole, amphotericin B
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Alkaline Phosphatase, Antifungal Agents, Aspartate Aminotransferases, Candidiasis, Double-Blind Method, Female, Humans, Male, Middle Aged, Phlebitis, Treatment Outcome, Echinocandins, Lipopeptides, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.